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Abstract
Background For 10 consecutive years, the ESPN/ERA-EDTARegistry has included data on childrenwith stage 5 chronic kidney
disease (CKD 5) receiving kidney replacement therapy (KRT) in Europe. We examined trends in incidence and prevalence of
KRT and patient survival.
Methods We included all children aged <15 years starting KRT 2007–2016 in 22 European countries participating in the ESPN/
ERA-EDTA Registry since 2007. General population statistics were derived from Eurostat. Incidence and prevalence were
expressed per million age-related population (pmarp) and time trends studied with JoinPoint regression. We analyzed survival
trends using Cox regression.
Results Incidence of children commencing KRT <15 years remained stable over the study period, varying between 5.5 and
6.6 pmarp. Incidence by treatment modality was unchanged over time: 2.0 for hemodialysis (HD) and peritoneal dialysis (PD)
and 1.0 for transplantation. Prevalence increased in all age categories and overall rose 2% annually from 26.4 pmarp in 2007 to
32.1 pmarp in 2016. Kidney transplantation prevalence increased 5.1% annually 2007–2009, followed by 1.5% increase/year
until 2016. Prevalence of PD steadily increased 1.4% per year over the entire period, and HD prevalence started increasing 6.1%
per year from 2011 onwards. Five-year unadjusted patient survival on KRTwas around 94% and similar for those initiating KRT
2007–2009 or 2010–2012 (adjusted HR: 0.98, 95% CI:0.71–1.35).
Conclusions We found a stable incidence and increasing prevalence of European children on KRT 2007–2016. Five-year patient
survival was good and was unchanged over time. These data can inform patients and healthcare providers and aid health policy
makers on future resource planning of pediatric KRT in Europe.
Keywords Dialysis . Peritoneal dialysis . Hemodialysis . Transplantation . Pediatrics . Epidemiology . ESPN/ERA-EDTA
Registry
Introduction
After decades of continuous growth, the incidence of kidney
replacement therapy (KRT) for stage 5 chronic kidney disease
(CKD 5) in European adult patients has slightly declined dur-
ing the last decade, whereas the increase in prevalence has
started to slow down and patient survival has improved [1].
CKD 5 etiologies in children are notably different from those
in adults, as kidney failure at pediatric age is mostly caused by
congenital or hereditary disorders rather than by diabetes or hy-
pertension which are the most common causes in adults [2, 3].
Despite major improvements in pediatric nephrology care over
the past 30–40 years, mortality on KRT remains 30 times higher
compared to healthy peers [4, 5]. Moreover, improved patient
care has resulted in the acceptance of more challenging patients
into pediatric KRT programs, including very young patients and
patients with more comorbidities [4].
For pediatric patients from the USA, the incidence of KRT
decreased by 21% since 2004 after a long period of increasing
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incidence rates, whereas the prevalence was stable over the
last decade [6]. Furthermore, in Australia and New Zealand,
the incidence rate varied widely from year to year, but
remained overall stable over the past 20 years. On the other
hand, the prevalence of pediatric KRT in Australia increased,
whereas there was no trend in New Zealand [7]. Data on
trends in pediatric KRT are important to inform patients and
healthcare providers and to aid healthy policy makers on fu-
ture resource planning of pediatric KRT in Europe. Earlier
European data showed a rise in KRT incidence in the 1980s
which remained stable thereafter, while the prevalence of
KRT among patients aged less than 20 years tripled from
1980 to 2000 [8]. However, more recent data on the incidence
and prevalence of pediatric KRT in Europe have only been
reported over a short time frame [4], and trends were not
studied.
With 10 consecutive years of data collection on European
pediatric KRT patients within the ESPN/ERA-EDTA
Registry, we are now able to report on trends in the incidence,
prevalence, treatment modality, and patient survival from
2007 to 2016.
Methods
Patient data were extracted from the ESPN/ERA-EDTA
Registry, a population-based registry that collects data on in-
dividual pediatric patients on KRT in Europe on an annual
basis [9, 10]. Currently, 36 countries participate in the
Registry. Most countries report information from pediatric
centers only. As older children (15–19 years of age) may be
treated in adult centers, they might not be included in the
ESPN/ERA-EDTA Registry, possibly leading to an underes-
timation of incidence and prevalence figures. Therefore, for
this study, we included data of patients initiating KRT <
15 years of age from the 22 countries contributing with data
on all treatment modalities for the entire period from January
1, 2007, to December 31, 2016 (Fig. 1). For comparison rea-
sons, we also report incidence and prevalence rates for the
other countries, but these numbers are not included in the
trend analyses.
Data were categorized as follows: age at initiation of KRT
(for incidence) or at the 31st of December of each year (for
prevalence) (0 < 5 years, 5 < 10 years, 10 < 15 years), sex
(male or female), treatment modality (hemodialysis (HD),
peritoneal dialysis (PD), or kidney transplantation), cause of
CKD 5 (categorized according to the ERA-EDTA coding sys-
tem adapted for children) [3], calendar year (2007 to 2016).
Incidence rates per million age-related population (pmarp)
were calculated as the number of new cases on KRT in each
calendar year divided by the mid-year age-related general
population. General population characteristics were extracted
from the Eurostat database [11].
Prevalence was calculated as the number of cases being
alive and treated with KRT on the 31st of December of each
calendar year and expressed as pmarp using the mid-year gen-
eral population.
To evaluate time trends in the observed incidence and prev-
alence, the JoinPoint regression program provided by the
Surveillance Research Program of the US National Cancer
Institute was used. The annual percentage change (APC)
was computed using Poisson regression provided by the
JoinPoint regression program, as described previously by
Kramer et al. [12]. In short, the program fits a series of joint
straight lines on a log scale to the trends in observed rates.
Line segments are joined at points called joinpoints, and each
joinpoint denotes a statistically significant change in trend.
The APC (i.e., the slope of the line segment) was calculated
with the observed rate as outcome variable and year as explan-
atory variable, in order to describe and test the significance of
the trends.
Patient survival probabilities were defined as the probabil-
ity that a person has survived up to a specific time point, e.g.,
1, 2, or 5 years after commencing KRT or after receiving a
first kidney transplant, and causes of death were classified
according to the ERA-EDTA Registry coding system, where-
as cardiac failure, cardiac arrest/sudden death, myocardial is-
chemia and infarction, and cerebro-vascular accidents were
combined as cardiovascular mortality [3]. Patients were
followed from the first day of KRT (patient survival on
KRT) or from the day of first kidney transplant (patient sur-
vival after transplantation) until death, lost to follow-up or end
of study, whichever occurred first.
The annual number of kidney transplants performed
(pmarp) between 2007 and 2016 was calculated, as well as
the 1-, 2 -, and 5-year graft survival, defined as being alive
Fig. 1 European countries included in the study
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with a functioning kidney transplant at 1, 2, or 5 years after
transplantation, respectively.
The Cox proportional hazard regression model was used to
calculate patient and graft survival probabilities, while ac-
counting for confounders. To compare adjusted 5-year surviv-
al between two periods of initiating KRT (2007–2009 and
2010–2012), adjusted hazard ratios were calculated using
Cox proportional hazard regression models. Adjustments
were made for the confounding effects of country, sex, cause
of CKD 5, and age and treatment modality at start of KRT.
Analyses were performed using SAS 9.4 statistical soft-
ware package (SAS Institute, Cary, NC, USA) and JoinPoint
version 4.7.0.0.




A total of 4459 patients aged 0–14 years from 22 European
countries initiated KRT between 2007 and 2016. The yearly
incidence of patients under 15 years commencing KRT by
country fluctuated considerably from year to year (Table 1).
The overall KRT incidence in Europe ranged between
5.5 pmarp and 6.6 pmarp, corresponding to 401 and 482 pa-
tients initiating KRT annually. There was no trend in the over-
all incidence in Europe from 2007 to 2016 (APC: − 0.8, 95%
CI: − 2.5 to 1.0).
The incidence of HD tended to decrease from 2.6 pmarp in
2007 to 2.0 pmarp in 2011 and to gradually increase back to
2.6 pmarp in 2014 and 2015, but these changes were not
statistically significant (Fig. 2a). The incidence of PD fluctu-
ated between 2.0 pmarp and 3.0 pmarp, but there was no
significant trend between 2007 and 2016 (APC: − 1.5, 95%
CI: − 4.0 to 1.1). The pre-emptive transplantation rate showed
amore stable pattern and was around 1.0 pmarp over the entire
period (Fig. 2a). The distribution of first treatment modality
was stable, with 80% of patients commencing KRT on dialy-
sis (HD and PD both 40%), while 20% received a pre-emptive
kidney transplant (Fig. 2b).
Figure 3 shows the incidence rate by age group for all
countries combined. The incidence rate was the highest
among 10–14-year-old patients (ranging from 7.1 to
8.5 pmarp) and the lowest among patients aged 5–9 years
(ranging from 4.1 to 5.4 pmarp), while it ranged from 5.5 to
6.4 pmarp in the youngest patients (< 5 years). Although the
incidence rate by age group fluctuated, there were no clear
trends in incidence rate according to age group.
A statistically significant decrease in incidence rate was
observed for patients with congenital anomalies of the kidney
and urinary tract (CAKUT) (APC: − 3.3, 95% CI: − 5.5 to −
1.0) and metabolic disorders (APC: − 8.1, 95% CI: − 14.3 to
− 1.5) leading to CKD 5, whereas the incidence rate of un-
known or missing causes of CKD 5 increased significantly by
5.2% annually (95% CI: 1.1 to 9.4) between 2007 and 2016.
Although not statistically significant, we observed a tendency
towards decreasing numbers of patients commencing KRT
due to vasculitis and hemolytic uremic syndrome (HUS).
The incidence of KRT due to other causes remained stable
over the study period (Table 2).
Trends in prevalence
The prevalence by country and year is shown in Table 3.
There were large country differences, but the overall preva-
lence increased by 1.9% annually (95% CI: 1.5–2.3) from
2120 children (29.5 pmarp) on KRT on December 31st,
2007, to 2675 children on KRT (35.6 pmarp) on December
31st, 2016.
The prevalence of patients on all three treatment modalities
increased during the study period (Fig. 4). For transplantation,
the increase was the strongest in the first 3 years, with an
annual change of 5.1% (95%CI: 1.8–8.6), whereas the annual
increase was 1.5% (95% CI: 1.1–1.9) for the following years.
The HD prevalence started to increase from 2011 onwards
with 6.1% annually (95% CI: 2.2–10.0), while PD prevalence
steadily increased by 1.4% annually (95% CI: 0.1–2.7) be-
tween 2007 and 2016.
For all age groups, the prevalence increased (Fig. 5). The
smallest increase was observed for the youngest patients
(APC: 1.6%, 95% CI: 0.5–2.7), while the strongest increase
was observed for patients aged 10–14 years between the years
2007 and 2009, with an annual increase of 4.6% (95% CI:
1.5–7.8%). In the period thereafter, the prevalence for 10–
14-year-old patients increased by 1.3% annually.
Patient survival on KRT and causes of death
During follow-up, 225 patients died after a median follow-up
of 4.1 years (IQR: 1.9–6.4). Overall 1-, 2-, and 5-year patient
survival were 97.6% (95% CI: 97.1–98.1), 96.4% (95% CI:
95.8–96.9), and 94.4% (95% CI: 93.6–95.2), respectively.
Similar adjusted survival probabilities were found (Table 4).
Most patients died from cardiovascular disease (28.9%),
followed by infections (22.7%), and for 23.1% of patients,
the cause of death was missing or unknown.
For patients commencing KRT in the period 2007–2009,
the 5-year unadjusted survival probability was 93.9% (95%
CI: 92.6–95.2), whereas it was 93.3% (95%CI: 91.8–94.7) for
patients commencing KRT between 2010 and 2012. After
adjustment for age, sex, cause of CKD 5, and treatment mo-
dality at start, the patient survival at 1, 2 (data not shown), and
5 years did not differ between the periods (adjusted HR 2010–
2012 vs. 2007–2009: 0.98, 95% CI: 0.71–1.35). The causes of
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Table 1 Incidence of KRT (pmarp) among 0–14-year-old children by country and year
Country Year
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Average
Albania* 3.1 1.6 3.4 1.7 0.0 9.3 9.5 4.1
Austria 7.0 5.5 10.4 4.0 7.3 4.1 1.6 6.5 4.0 6.4 5.7
Belarus* 5.6 4.2 5.0 4.9 4.2 5.4 5.3 3.9 3.8 4.7
Belgium* 7.8 2.8 3.3 6.5 3.7 2.6 4.4
Bosnia and Herzegovina* 8.2 3.3 8.2 5.2 3.7 1.8 5.1
Bulgaria* 4.1 4.1 3.1 5.1 2.0 3.0 9.0 2.0 4.2
Croatia* 8.8 8.9 4.5 6.1 7.8 6.3 6.4 4.9 11.5 7.2
Cyprus* 0.0 7.2 21.5 14.3 10.8
Czech Republic 6.1 2.7 4.0 4.6 6.5 2.6 5.1 5.7 5.0 4.3 4.7
Denmark 9.9 6.9 16.9 7.0 5.0 7.1 8.2 7.2 5.2 5.2 7.9
Estonia 0.0 5.0 0.0 0.0 4.9 0.0 0.0 0.0 9.5 0.0 1.9
Finland 12.3 4.5 6.7 9.0 6.8 9.0 9.0 12.3 14.5 3.4 8.7
France 6.6 6.4 6.3 6.3 4.9 5.1 6.5 5.4 7.4 6.7 6.2
Georgia* 2.6 12.7 7.4 5.6 7.1
Germany CERTAIN*1 3.6 2.0 1.2 0.6 0.6 0.2 0.9 1.3
Germany KfH*2 2.5 2.8 3.9 3.1
Greece 8.0 6.8 8.0 4.3 3.1 6.8 1.9 5.7 5.7 2.6 5.3
Hungary 3.3 4.0 9.4 4.8 5.5 7.7 7.0 6.3 14.7 6.3 6.9
Iceland 15.2 0.0 0.0 15.0 15.1 0.0 15.0 0.0 0.0 0.0 6.0
Ireland* 11.9 11.9
Italy*3 4.5 4.5 4.7 3.2 3.6 4.7 3.9 4.3 3.5 3.0 4.0
Latvia* 3.4 3.3 3.4
Lithuania 3.9 2.0 8.4 0.0 2.2 6.8 6.9 0.0 9.4 2.4 4.2
Malta* 0.0 0.0 0.0 0.0 0.0 0.0 15.5 2.2
Moldova* 1.7 1.7 1.7
Montenegro* 0.0 24.5 0.0 8.2
North Macedonia 7.9 0.0 2.7 2.8 2.8 0.0 5.7 0.0 2.9 0.0 2.5
the Netherlands 7.5 7.9 8.2 6.9 4.8 6.2 5.9 6.3 7.1 6.4 6.7
Norway 5.5 7.7 10.9 4.3 10.8 5.4 5.4 9.7 11.8 5.3 7.7
Poland* 6.9 6.6 6.5 6.9 6.0 4.3 4.9 7.0 4.0 5.9
Portugal 9.1 7.3 10.5 5.0 9.5 12.2 4.6 8.6 6.8 4.8 7.9
Romania 2.3 5.2 5.0 4.7 6.3 4.7 4.5 3.2 3.3 3.9 4.3
Russia 4.4 3.7 3.4 3.9 3.5 4.8 3.6 4.9 3.5 3.3 3.9
Serbia 4.4 11.5 3.6 2.8 4.8 2.9 5.8 5.9 4.9 4.9 5.2
Slovakia 4.6 3.5 6.0 3.6 4.8 2.4 6.0 7.2 3.6 2.4 4.4
Slovenia 7.1 14.2 3.5 10.4 3.4 3.4 6.7 19.8 3.3 9.8 8.2
Spain 6.7 7.4 8.3 5.4 7.1 5.8 6.5 6.2 6.0 7.1 6.6
Sweden 7.1 7.1 9.7 12.2 8.3 13.1 8.6 9.6 5.9 8.6 9.0
Switzerland*4 5.1 4.3 3.4 8.4 11.7 3.3 4.9 9.7 7.2 6.4
Turkey*5 3.0 3.1 3.1 3.2 4.1 3.2 3.3 3.3
Ukraine* 0.9 3.1 4.9 3.6 3.9 2.9 4.0 3.3
UK 11.0 11.0 9.6 8.2 7.8 9.6 9.5 10.6 10.7 8.9 9.7
Total 6.5 6.3 6.6 5.6 5.5 6.1 5.8 6.4 6.3 5.5 6.1
KRT, kidney replacement therapy; pmarp, per million age-related population
*Not included in the total incidence
1Data are based on transplantation patients only; therefore, the numbers are an underestimation of the true incidence in Germany. The coverage ranged
from 12 out of 20 centers in 2010 to 18 out of 20 centers in 2016. Each year around 120 patients under the age of 21 years are transplanted, of which 16%
pre-emptively
2Dialysis patients only. In 2015, data from one dialysis center was not included, and the incidence of dialysis patients is an underestimation of the true
incidence
3 (Pre-emptive) transplantation patients are not included;
4 In 2013, not all patients provided informed consent resulting in an underestimation of the true incidence;
5 For 2010, data are based on patients aged 0–15 years. The incidence is an underestimation of the true incidence
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death differed by period (Table 5). Patients who commenced
KRT between 2007 and 2009 died more often from infections
(31.3%), whereas cardiovascular disease was more often the
cause of death (41.3%) for patients who commenced KRT
between 2010 and 2012 (P < 0.001).
Kidney transplantation and graft survival
The overall number of kidney transplants (pre-emptive and
non-pre-emptive, deceased and living donor) performed annu-
ally was stable and varied between from 3.1 to 3.9 pmarp
(APC: − 1.4%, 95% CI: − 2.8–0.1).
Overall unadjusted graft survival was 94.4% (95%
CI: 93.5–95.3) at 1 year and 89.1% (95% CI: 87.8–
90.5) at 5 years post-transplantation. Graft survival var-
ied by year between 90.8% (95% CI: 87.3–94.4) and
97.0% (95% CI: 94.8–99.2) at 1 year and between
87.1% (95% CI: 83.2–91.2) and 94.1% (95% CI:
91.2–97.0) at 5 years after transplantation, but did not
change over time (Table 6).
Overall unadjusted patient survival after transplantation
was 98.8% (95% CI: 98.4–99.3), 98.5% (95% CI: 97.9–
99.0), and 97.2% (95% CI: 96.3–98.1) at 1, 2, and 5 years
post-transplantation, respectively.
Discussion
In this ESPN/ERA-EDTA Registry study, we found a
stable incidence and an increasing prevalence of nearly
2% per year in European pediatric KRT over the last
decade. The first mode of KRT was stable over time,
with the majority of patients initiating KRT on dialysis
(both HD and PD 40%), and 20% of patients received a
pre-emptive kidney transplant. Patient survival was good
and did not change over time, but we found a shift in
causes of death. Patients who commenced KRT before
2010 died more often from infectious causes, whereas
patients commencing KRT later were more likely to die
from cardiovascular disease.
Fig. 2 Incidence of KRT by
treatment modality and year. a
Trends in the incidence rate of
pediatric KRT by treatment
modality (pmarp). Trends were
calculated by the APC and its
95% confidence interval. b
Distribution of first KRT
modality by year. Abbreviations:
KRT, kidney replacement
therapy; pmarp, per million age-
related population; APC, annual
percentage change; HD,
hemodialysis; PD, peritoneal




A previous ERA-EDTA Registry study reported a stable inci-
dence for patients initiating KRT at an age below 19 years of
age between 1997 and 2006 [12]. Similarly, we found a stable
overall incidence of European patients commencing KRT be-
fore the age of 15 years over the last decade. Also, in Australia
and New Zealand, the overall trend in the incidence of treated
CKD 5 patients <18 years was stable for the past 20 years [7].
A more recent ERA-EDTA Registry study, studying the years
2001 to 2011, reported a small decrease of 2.5% per year in
the incidence of European patients below 19 years [1].
Although the incidence increased prior to 2004, also in the
USA, the incidence of children (0–21 years of age) requiring
KRT has steadily declined between 2004 and 2016 [6].
Differences between our study and the other cohorts might
in part be caused by different age limits of included patients,
as well as by differences in the years studied. However, none
of the recent studies reported an increase in incident pediatric
patients requiring KRT for CKD 5, suggesting that pediatric
nephrologists are succeeding in their efforts to prevent pro-
gression to stage 5 CKD.
In adults, lifestyle-related diseases such as hypertension,
diabetes, and obesity are important risk factors for CKD
[13]. Although there are some studies reporting similar asso-
ciations for the pediatric population [14, 15], causes of CKD 5
in children are mostly of congenital and hereditary origin [2].
We did, however, observe changes in the causes of kidney
disease over time. The number of children who needed KRT
due to CAKUT decreased on average by 3.3% per year over
the 10-year study period. According to the European network
of congenital anomaly registries, there were more live births
of children with congenital urinary anomalies in the same
period [16], which might further strengthen the hypothesis
of successful pre-CKD 5 treatment in this category of
European children with CKD. We also found a decrease in
the number of children initiating KRT due to rare diseases,
such as metabolic disorders, HUS, and vasculitis, which might
Fig. 3 Incidence of KRT (pmarp)
by age group and year. Trends
were calculated by the APC and
its 95% confidence interval.
Abbreviations: KRT, kidney
replacement therapy; pmarp, per
million age-related population;
APC, annual percentage change
Table 2 Incidence (pmarp) by cause of stage 5 CKD and year
Cause of CKD 5 Year APC
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Glomerulonephritis 1.0 1.0 1.0 0.8 1.0 0.8 0.8 0.8 0.9 0.9 −1.0 (−4.0;+2.0)
CAKUT 2.7 2.4 2.7 2.4 2.2 2.6 2.2 2.2 2.3 1.7 −3.3 (−5.5; −1.0)*
Cystic kidneys 0.7 0.8 0.5 0.5 0.8 0.7 0.8 0.9 0.9 0.6 +2.0 (−2.8;+7.1)
Hereditary nephropathy 0.4 0.4 0.5 0.3 0.4 0.4 0.6 0.5 0.4 0.5 +1.8(−2.7;+6.5)
Ischemic kidney failure 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 −5.0 (−11.7;+2.1)
HUS 0.3 0.4 0.3 0.3 0.2 0.2 0.2 0.3 0.2 0.2 −4.9 (−9.7;+0.1)
Metabolic disorder 0.2 0.3 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.1 −8.1 (−14.3;-1.5)*
Vasculitis 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 −9.0 (−18.0;+0.8)
Miscellaneous 0.6 0.4 0.6 0.5 0.3 0.5 0.4 0.7 0.8 0.9 +6.1 (−0.8;+13.6)
Missing/unknown 0.4 0.3 0.4 0.4 0.4 0.6 0.6 0.6 0.5 0.5 +5.2 (+1.1;+9.4)*
pmarp, per million age-related population; CKD 5, stage 5 chronic kidney disease; CAKUT, congenital anomalies of the kidney and the urinary tract;
HUS, hemolytic uremic syndrome
* Statistically significant trend
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Table 3 Prevalence of KRT (pmarp) among 0–14-year-old children by country and year
Country Year
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Average
Albania* 4.7 4.9 8.5 7.0 7.2 11.1 9.5 7.5
Austria 40.4 41.8 46.3 40.3 43.1 40.1 36.9 38.4 40.4 41.4 40.9
Belarus* 19.0 20.5 21.2 22.5 20.8 21.7 23.3 24.8 24.3 22.0
Belgium* 57.2 53.7 49.3 46.1 36.6 48.6
Bosnia and Herzegovina* 14.8 14.8 18.1 20.9 20.2 20.2 18.2
Bulgaria* 17.3 10.7 11.7 10.2 12.5 13.1 8.0 18.0 10.0 12.4
Croatia* 29.4 32.5 29.9 30.3 40.6 42.7 36.8 40.6 51.0 37.1
Cyprus* 35.5 50.2 64.4 71.7 55.4
Czech Republic 23.8 21.7 22.2 22.5 26.8 22.6 22.9 26.4 28.5 27.5 24.6
Denmark 42.5 40.6 50.8 51.1 49.5 54.0 49.3 43.5 38.4 40.5 46.1
Estonia 10.0 15.1 10.0 4.9 9.8 9.7 9.6 9.6 19.0 18.8 11.7
Finland 92.4 80.6 80.9 82.2 84.4 85.4 85.1 89.3 97.0 80.4 85.8
France 30.1 32.9 35.6 36.0 35.8 35.3 36.9 37.8 39.0 39.0 35.9
Georgia* 7.8 18.3 19.1 20.9 16.5
Germany CERTAIN*1 20.5 17.6 21.6 16.8 19.2 20.2 22.7 19.8
Germany KfH*2 10.8 11.9 14.2 12.3
Greece 29.0 30.2 33.8 35.0 32.0 37.0 32.3 34.0 36.4 34.0 33.4
Hungary 32.9 28.7 33.0 29.3 30.4 33.4 37.8 35.8 38.6 40.7 34.0
Iceland 30.4 30.2 30.1 45.1 60.2 60.3 60.0 59.8 59.9 45.0 48.1
Ireland* 75.5 75.5
Italy*3 29.7 31.6 31.2 30.3 30.4 31.4 32.0 32.7 31.2 30.7 31.1
Latvia* 16.9 16.7 16.8
Lithuania 33.4 34.7 42.0 28.1 24.5 22.7 25.4 18.7 18.8 21.3 27.3
Malta* 63.7 64.6 65.0 64.9 64.2 31.6 31.0 55.0
Moldova* 6.9 1.7 4.3
Montenegro* 8.1 32.7 32.8 24.5
North Macedonia 18.3 16.0 19.1 19.4 22.4 14.2 17.2 11.5 14.4 14.5 16.8
the Netherlands 44.1 43.7 45.9 44.3 43.8 44.0 42.9 42.6 44.1 45.5 44.1
Norway 47.4 44.0 47.0 41.3 46.6 47.5 45.2 49.4 57.9 56.6 48.3
Poland* 34.4 34.8 37.7 40.6 40.6 40.8 41.0 40.1 38.7 38.7
Portugal 38.2 40.9 44.9 45.4 50.5 59.6 54.7 57.1 56.3 50.3 49.6
Romania 6.1 9.7 12.1 11.9 13.5 15.2 15.1 13.9 14.0 16.0 12.6
Russia 9.4 11.0 12.0 13.0 14.3 16.3 16.3 18.0 18.5 18.8 14.9
Serbia 24.5 35.6 35.9 31.5 29.7 30.0 29.2 28.3 30.3 29.5 30.4
Slovakia 27.8 26.0 27.5 26.4 25.2 21.6 26.5 21.7 20.5 19.1 24.2
Slovenia 17.8 31.9 31.5 38.1 34.2 37.1 30.0 36.3 22.9 32.5 31.3
Spain 39.7 40.4 42.2 39.2 41.4 39.9 40.3 41.0 41.0 43.3 40.6
Sweden 49.8 46.7 49.8 55.2 54.0 59.4 57.7 63.7 57.1 58.1 55.3
Switzerland*4 44.1 42.4 42.2 42.7 48.3 42.1 42.4 42.0 56.6 44.7
Turkey* 32.1 16.0 17.4 17.7 13.3 14.3 15.7 18.1
Ukraine* 8.3 7.8 10.0 11.6 13.2 12.5 13.4 11.0
UK 53.1 53.7 53.8 52.7 50.6 50.9 50.8 53.5 55.8 55.9 53.1
Total 29.4 30.6 32.4 32.0 32.5 33.4 33.3 34.4 35.3 35.6 32.9
KRT, kidney replacement therapy; pmarp, per million age-related population
*Not included in the total prevalence
1Data are based on transplantation patients only; therefore, the numbers are an underestimation of the true prevalence in Germany. The coverage ranged
from 12 out of 20 centers in 2010 to 18 out of 20 centers in 2016. Each year around 120 patients under the age of 21 years are transplanted, of which 16%
pre-emptively
2Dialysis patients only. In 2015, data from one dialysis center was not included, and the prevalence of dialysis patients is an underestimation of the true
incidence
3 (Pre-emptive) transplantation patients are not included; the prevalence is an underestimation of the true prevalence
4 In 2013 and 2014, not all patients provided informed consent resulting in an underestimation of the true prevalence
5 For 2010, data are based on patients aged 0–15 years. The prevalence is an underestimation of the true prevalence
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be the result of advances in timely and more accurate diagno-
sis, as well as the emergence of new therapeutics (i.e., bio-
logics and monoclonal antibodies). At the same time, we
found an increase in the number of children initiating KRT
because of an unknown or missing cause of CKD 5. Although
this might be due to a registration issue, it could also suggest
that the number of complex cases, in which it is difficult to
identify a single or clear diagnosis, accepted into KRT pro-
grams is increasing. Furthermore, it might also be the result of
late referral, which might imply that fewer biopsies were per-
formed. Indeed, in a UK study, patients with an uncertain
etiology were more likely to be referred late [17].
Prevalence
In accordance with findings in European adults [1] and in
Australian children [7], this study found that the overall prev-
alence of European children on KRT has increased by nearly
2% per year over the 10-year study period. In contrast, the
prevalence of KRT for pediatric patients from the USA and
from New Zealand remained stable for the most recent decade
[6, 7]. In the US, the incidence rate decreased and the survival
improved resulting in a stable prevalence rate [6].
We observed an increasing trend in prevalence for all
age groups and for all treatment modalities. Throughout
the study period, the prevalence for both dialysis mo-
dalities was similar, whereas the number of patients liv-
ing with a functioning transplant was about 4 to 5 times
larger than the number of patients treated with dialysis.
We did not find any further improvement in patient
survival, but as long as the number of new CKD 5
cases is higher than the numbers of deaths, the preva-
lence rate will continue to grow.
Mortality
Overall, 1- and 5-year patient survival on KRT were 98% and
94%, respectively, and are similar to or slightly higher than
rates reported in other high-income countries [18].We found a
stable patient survival throughout the decade. Although the 1-
year patient mortality has decreased by 20% over the last
decade in US pediatric patients, the 5-year survival probability
for those starting KRT from 2002 to 2006 was 89% [19],
whereas it was 91% for those starting KRT between 2007
and 2011 [6] and therefore patient survival in the US was
lower than that in Europe.
Fig. 4 Prevalence of KRT
(pmarp) by treatment modality
and year. Trends were calculated
by the APC and its 95%
confidence interval.
Abbreviations: KRT, kidney
replacement therapy; pmarp, per
million age-related population;
APC, annual percentage change,
HD, hemodialysis; PD, peritoneal
dialysis; Tx, kidney
transplantation
Fig. 5 Prevalence of KRT
(pmarp) by age group and year.
Trends were calculated by the
APC and its 95% confidence
interval. Abbreviations: KRT,
kidney replacement therapy;




The improvement in patient survival of pediatric KRT has
possibly reached its ceiling, but mortality remains at least 30
times higher than in the general pediatric population [18].
Patients initiating KRT between 2007 and 2009 died
more often from infections, whereas cardiovascular dis-
ease was the leading cause of death for patients initiat-
ing KRT between 2010 and 2012. Although others also
reported cardiovascular disease and infections to be the
leading causes of death in pediatric KRT patients [6,
20–22], a decrease in cardiovascular mortality due to
vigorous cardioprotective management has been
reported. However, these findings were mainly based
on data from patients treated during the last decades
of the twentieth century or from adult patients who
commenced KRT during childhood [20, 22–24]. Due
to a high number of cases for whom the cause of death
was reported as unknown or missing, as well as the
relatively short period of time, we cannot draw any
conclusions about trends in causes of death over time.
Future studies with longer periods of follow-up are
needed to determine whether a trend towards higher
cardiovascular mortality exists in the European pediatric
KRT population, and which specific factors are
involved.
Kidney transplantation
We did not find an overall trend in the number of kidney
transplants performed. Also the graft survival remained stable
over time. The prevalence of kidney transplantation increased
over the decade as the incidence of kidney transplantation
continues to outweigh the number of patients whose kidney
graft fails. One-year graft survival remained stable over the
study period ranging from 91.5 to 97.3%. Overall graft sur-
vival was 94% at 1 year and 89% at 5 years and thereby
slightly higher than in registry studies from Australia and
New Zealand (83%) and the USA (86% for living donor kid-
neys and 79% for deceased donor kidneys) [7, 25].
As with every KRT registry, a limitation of our study is that
only CKD 5 patients treated with KRT are included, and the
numbers presented in this study do not reflect pediatric pa-
tients with CKD 5 not (yet) on KRT. Furthermore, only coun-
tries that participated in the ESPN/ERA-EDTA Registry for
the entire study period of 2007 to 2016 are included in the
current study, and our study might not be fully representative
Table 4 Unadjusted and adjusted KRT patient survival probabilities
Period Unadjusted patient survival probability (95% CI) Adjusted patient survival probability (95% CI)
1 year 2 years 5 years 1 year 2 years 5 years
2007 97.2 (95.7–98.7) 95.7 (93.9–97.6) 94.1 (92.0–96.3) 98.1 (96.9–99.3) 96.7 (95.4–98.6) 95.8 (93.9–97.9)
2008 96.7 (95.0–98.3) 95.8 (93.9–97.6) 93.4 (91.1–95.7) 97.5 (96.1–98.9) 96.8 (95.2–98.4) 94.9 (92.8–97.1)
2009 97.0 (95.5–98.6) 95.5 (93.6–97.4) 94.2 (92.1–96.3) 97.5 (96.1–98.9) 96.5 (94.8–98.2) 95.4 (93.4–97.5)
2010 96.3 (94.4–98.1) 95.3 (93.2–97.4) 93.7 (91.4–96.1) 98.6 (97.4–99.7) 98.2 (96.8–99.6) 97.5 (95.8–99.3)
2011 98.2 (96.9–99.5) 96.1 (94.2–98.1) 93.4 (91.5–96.4) 98.4 (97.2–99.6) 96.5 (94.7–98.5) 94.6 (92.2–97.1)
2012 96.6 (94.4–98.0) 95.0 (93.0–97.1) 97.1 (95.5–98.7) 96.2 (94.4–98.1)
2013 97.7 (96.2–99.1) 96.7 (95.3–98.6) 99.4 (98.5–100) 99.2 (98.3–100)
2014 98.5 (97.4–99.6) 97.7 (96.3–99.0) 99.9 (88.2–100) 99.9 (82.7–100)
2015 99.6 (99.0–100) 99.8 (84.9–100)
2007–2016 97.6 (97.1–98.1) 96.4 (95.8–96.9) 94.4 (93.6–95.2) 98.2 (97.8–98.6) 97.3 (96.8–97.8) 95.8 (95.0–96.5)
*Adjusted for fixed values for age at KRT (8.5 years), male sex (59%), glomerulonephritis (15%), CAKUT (38%), hereditary nephropathy (12%), and
cystic kidney disease (7%)
Table 5 Causes of death by period of initiating KRT
Cause of death Period of initiating KRT
N (%)
2007–2009 2010–2012
Cardiovascular disease1 18 (21.7) 33 (41.3)
Infections2 26 (31.3) 10 (12.5)
Malignancies3 7 (8.4) 1 (1.3)
Other identified causes4 17 (20.5) 11 (13.8)
Unknown/missing 15 (18.1) 25 (31.3)
KRT, kidney replacement therapy;CKD 5, stage 5 chronic kidney disease
1 Cardiac arrest/sudden death, fluid overload/pulmonary edema, cerebro-
vascular accident, other cause of cardiac failure; 2 Pulmonary infection
(bacterial, viral, parasitic), infections elsewhere, septicemia, generalized
viral infection, (bacterial) peritonitis; 3 Solid tumors, malignancies possi-
bly induced by immunosuppressive therapy; 4 Hyperkalemia, pulmonary
embolus, other hemorrhage, uremia caused by graft failure, chronic ob-
structive airway disease, accident unrelated to CKD 5 treatment, patient
refused further treatment of CKD 5, CKD 5 treatment withdrawn for
medical reasons, malignant disease possibly induced by immunosuppres-
sive therapy, malignant disease: solid tumors, other identified cause of
death
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for the whole of Europe. However, our study is the first one to
provide data on trends in incidence, prevalence, and rates of
kidney transplantation and patient survival for European pe-
diatric KRT patients over a 10-year period.
In conclusion, we found a stable incidence and an increas-
ing prevalence of European children on KRT over the past
decade. Five-year patient survival was good and did not
change over time. Also, the annual number of kidney trans-
plantations performed did not change. These data can be used
for future resource planning of pediatric KRT in Europe.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s00467-021-04928-w.
Acknowledgments Wewould like to thank the patients, their parents, and
the staff of all the dialysis and transplant units who have contributed data
via their national registries and contact persons. We also would like to
thank R Topaloglu, J Oh, Z Massy, and MD Sinha for being members of
the ESPN/ERA-EDTA Registry Committee; D Shtiza, R Kramar, D
Pokrajac, K van Hoeck, and the Centre contributors to the Belgian
Registry Committee; A Sukalo, I Sheuchuk, O Liachovskaya, A
Dudarevic, D Kavalenka, E Maurer, GF Laube, CE Kuehni, H
Chehade, and the Swiss Paediatric Renal Registry; A Elia, T Seeman,
K Vondrak, K Krupka, B Höcker, L Pape, B Tönshoff, L Weber, G von
Gersdorff, J Dötsch, F Schaefer, K Hommel, Ü Toots, A Alonso Melgar,
and the Spanish Paediatric Registry; J Helve, P Finne, P-H Groop, C
Couchoud, M Lassalle, E Berard, T Davitaia, G Moustakas, A
Kapogiannis, A Mitsioni, N Printza, D Milosevic, M Ban, J Slavicek, D
Arapovic, S Abdovic, G Reusz, Cs Berecki, A Szabó, T Szabó, A Barczi,
O Lakatos, E Kis, A Awan, T Raftery, C Sweeney, N Dolan, M Riordan,
M Stack,MWaldron, R Palsson, V Edvardsson, B Gianoglio, E La Porta,
F Paglialonga, M Parolin, C Pecoraro, A Jankauskiene, S Rudiatis, A
Popova, V Kuzema, H Čerņevskis, S Gatcan, O Berbeca, N Zaikova, N
Revenco, E Sahpazova, N Abazi, S Pavićević, V Said-Conti, L
Heuveling, and MH Hemmelder on behalf of the Nefrovisie foundation;
JWGroothoff and all centers participating in the RichQ-study; A Åsberg,
AV Reisæter, A Zurowska, I Zagozdzon, C Mota, R Stone, C Simão, M
Kostić, B Spasojević, M Cvetković, I Gojković, D Paripović, G
Miloševski-Lomić, NA Tomilina, KG Prütz, M Stendahl, M Evans, S
Schön, M Segelmark, T Lundgren, L Podracka, G Kolvek, N Battelino,
G Novljan, J Buturovic-Ponikvar, S Bakkaloglu, DD Ivanov, SP Fomina,
L Plumb, F Braddon, A Casula, and H Maxwell for contributing data to
the ESPN/ERA-EDTA Registry.
Funding The ESPN/ERA-EDTA Registry is funded by the European
Society of Paediatric Nephrology (ESPN), and the European Renal
Association–European Dialysis and Transplant Association (ERA-
EDTA). Furthermore, Amgen has agreed to provide an unrestricted grant
to assist the ERA-EDTA on the financial support of the ESPN/ERA-
EDTA Registry. This article was written by M Bonthuis et al. on behalf
of the ESPN/ERA-EDTA Registry and the ERA-EDTA Registry which
is an official body of the ERA-EDTA (European Renal Association–
European Dialysis and Transplant Association).
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Pippias M, Jager KJ, Kramer A, Leivestad T, Sánchez MB, Caskey
FJ, Collart F, Couchoud C, Dekker FW, Finne P, Fouque D, Heaf
JG, HemmelderMH, Kramar R, DeMeester J, NoordzijM, Palsson
R, Pascual J, Zurriaga O, Wanner C, Stel VS (2016) The changing
Table 6 Unadjusted and adjusted 1-, 2-, and 5-year graft survival probabilities
Period Unadjusted graft survival probability (95% CI) Adjusted graft survival probability (95% CI)*
1 year 2 years 5 years 1 year 2 years 5 years
2007 90.8 (87.3–94.4) 89.6 (86.0–93.4) 87.2 (83.2–91.4) 91.2 (87.7–94.9) 90.1 (86.3–94.0) 87.7 (83.5–92.1)
2008 96.5 (94.3–98.8) 96.5 (94.3–98.8) 94.1 (91.2–97.0) 96.8 (94.7–99.0) 96.8 (94.7–99.0) 94.5 (91.6–97.5)
2009 93.3 (90.3–96.4) 90.9 (87.5–94.5) 86.8 (82.7–91.1) 94.6 (91.8–97.5) 92.6 (89.3–96.1) 89.2 (85.0–93.7)
2010 93.2 (90.3–96.2) 91.4 (88.1–94.8) 87.1 (83.2–91.2) 93.2 (90.3–96.3) 91.4 (88.0–94.9) 87.2 (83.1–91.5)
2011 94.2 (91.5–97.1) 92.3 (89.1–95.6) 86.3 (82.2–90.6) 94.6 (91.9–97.4) 92.7 (89.6–96.1) 87.1 (82.9–91.6)
2012 96.3 (94.0–98.7) 95.1 (92.4–97.8) 96.3 (94.0–98.8) 95.1 (92.4–98.0)
2013 95.3 (92.8–97.8) 94.1 (91.3–97.0) 96.3 (94.0–98.7) 95.4 (92.7–98.1)
2014 97.0 (94.8–99.2) 95.3 (92.6–98.0) 97.3 (95.2–99.5) 95.8 (93.0–98.6)
2015 93.6 (90.5–96.8) 93.7 (90.4–97.0)
2007–2016 94.4 (93.5–95.3) 93.0 (92.0–94.0) 89.1 (87.8–90.5) 94.6 (93.7–95.5) 93.3 (92.2–94.3) 89.4 (88.0–90.9)
*Adjusted for fixed values for age at transplant (8.9 years), male sex (61%), deceased donor (59%), glomerulonephritis (14%), CAKUT (34%),
hereditary nephropathy (11%), and cystic kidney disease (8%)
Pediatr Nephrol
trends and outcomes in renal replacement therapy: data from the
ERA-EDTA Registry. Nephrol Dial Transplant 31:831–841
2. ESPN/ERA-EDTA Registry: ESPN/ERA-EDTA Registry Annual
Report 2016. Amsterdam UMC, location AMC, Department of
Medical Informatics, Amsterdam, the Netherlands, 2018
3. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2017.
Amsterdam UMC, location AMC, Department of Medical
Informatics, Amsterdam, the Netherlands, 2019
4. Chesnaye N, Bonthuis M, Schaefer F, Groothoff JW, Verrina E,
Heaf JG, Jankauskiene A, Lukosiene V, Molchanova EA, Mota C,
Peco-Antić A, Ratsch IM, Bjerre A, Roussinov DL, Sukalo A,
Topaloglu R, van Hoeck K, Zagozdzon I, Jager KJ, van Stralen
KJ, ESPN/ERA-EDTA Registry (2014) Demographics of paediat-
ric renal replacement therapy in Europe: a report of the ESPN/ERA-
EDTA Registry. Pediatr Nephrol 29:2403–2410
5. Chavers BM, Molony JT, Solid CA, Rheault MN, Collins AJ
(2015) One-year mortality rates in US children with end-stage renal
disease. Am J Nephrol 41:121–128
6. United States Renal Data System. 2018 USRDS annual data report:
Epidemiology of kidney disease in the United States. National
Institutes of Health, National Institute of Diabetes and Digestive
and Kidney Diseases, Bethesda, MD, 2018
7. ANZDATA Registry. 41st report, chapter 11: Paediatric patients
with end stage kidney disease requiring renal replacement therapy,
Australia and New Zealand Dialysis and Transplant Registry,
Adelaide, 2018
8. van der Heijden BJ, van Dijk PCW, Verrier-Jones K, Jager KJ,
Briggs JD (2004) Renal replacement therapy in children: data from
12 registries in Europe. Pediatr Nephrol 19:213–221
9. Tizard EJ, Verrina E, van Stralen KJ, Jager KJ (2009) Progress with
the European Society for Paediatric Nephrology (ESPN)/ERA-
EDTA Registry for children with established renal failure (ERF).
Nephrol Dial Transplant 24:2615–2617
10. ESPN/ERA-EDTARegistry website. [Available from: https://espn-
reg.org/index.jsp]. Accessed on 13 January 2020
11. Eurostat website. [Available from: https://appsso.eurostat.ec.
europa.eu/nui/show.do?dataset=demo_pjan&lang=en]. Accessed
on 20 September 2019
12. Kramer A, Stel VS, Zoccali C, Heaf K, Ansell D, Grönhagen-Riska
C, Leivestad T, Simpson K, Pálsson R, Postorino M, Jager KJ,
ERA-EDTA Registry (2009) An update in renal replacement ther-
apy in Europe: ERA-EDTA Registry data from 1997 to 2006.
Nephrol Dial Transplant 24:3557–3566
13. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH,
Heerspink HJ, Mann JF, Matsuhita K, Wen CP (2013) Chronic
kidney disease and cardiovascular risk: epidemiology, mechanisms
and prevention. Lancet 382:339–352
14. Staples AO, Greenbaum LA, Smith JM, Gipson DS, Filler G,
Warady BA, Martz K, Wong CS (2010) Association between clin-
ical risk factors and progression of chronic kidney disease in chil-
dren. Clin J Am Soc Nephrol 5:2172–2179
15. Gunta SS, Mak RH (2013) Is obesity a risk factor for chronic kid-
ney disease in children? Pediatr Nephrol 28:1949–1956
16. European network of population-based registries for the epidemio-
logical surveillance of congenital anomalies (EUROCAT) website.
[Available from: https://eu-rd-platform.jrc.ec.europa.eu/eurocat_
en]. Accessed on 1 March 2020
17. Pruthi R, Casula A, Inward C, Roderick P, Sinha MD (2016) Early
requirement for RRT in children at presentation in the United
Kingdom: association with transplantation and survival. Clin J
Am Soc Nephrol 11:795–802
18. Chesnaye NC, van Stralen KJ, Bonthuis M, Harambat J, Groothoff
JW, Jager KJ (2018) Survival in children requiring chronic renal
replacement therapy. Pediatr Nephrol 33:585–594
19. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas
of Chronic Kidney Disease and End-Stage Renal Disease in the
United States, National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013
20. Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, van
deKar NJ,Wolff ED, Davin JC, Heymans HS (2002)Mortality and
causes of death of end-stage renal disease in children: a Dutch
cohort study. Kidney Int 61:621–629
21. McDonald SP, Graig JC, Australian and New Zealand Paediatric
Nephrology Association (2004) Long-term survival of children
with end-stage renal disease. N Engl J Med 350:2654–2662
22. Mitsnefes MM, Laskin BL, Dahhou M, Zhang X, Foster BJ (2013)
Mortality risk among children initially treated with dialysis for end-
stage kidney disease, 1990-2010. JAMA 309:1921–1929
23. Vogelzang JL, van Stralen KJ, Jager KJ, Groothoff JW (2013)
Trend from non-cardiovascular late mortality in patients with renal
replacement therapy since childhood. Nephrol Dial Transplant 28:
2082–2089
24. Vogelzang JL, Heestermans LWAA, van Stralen KJ, Jager KJ,
Groothoff JW (2013) Simultaneous reversal of risk factors for car-
diac death and intensified therapy in long-term survivors of paedi-
atric end-stage renal disease over the last 10 years. Nephrol Dial
Transplant 28:2545–2542
25. North American Pediatric Renal Trials and Collaborative Studies.
NAPRTCS 2014 Annu Rep, 2014
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Pediatr Nephrol
Affiliations
Marjolein Bonthuis1 & Enrico Vidal2 & Anna Bjerre3 & Özlem Aydoğ4 & Sergey Baiko5 & Liliana Garneata6 &
Isabella Guzzo7 & James G. Heaf8 & Timo Jahnukainen9 &Marc Lilien10 & Tamara Mallett11,12 & Gabriel Mirescu13,14 &
Elena A. Mochanova15 & Eva Nüsken16 & Katherine Rascher17 & Dimitar Roussinov18 &Maria Szczepanska19 &
Michel Tsimaratos20 & Askiti Varvara21 & Enrico Verrina22 & Bojana Veselinović23 & Kitty J. Jager1 & Jérôme Harambat24
1 ESPN/ERA-EDTA Registry, Amsterdam UMC, University of
Amsterdam, Department of Medical Informatics, Amsterdam Public
Health Research Institute, Meibergdreef 9,
Amsterdam, The Netherlands
2 Division of Pediatrics, Department of Medicine, University of
Udine, Udine, Italy
3 Division of Pediatric and Adolescent Medicine, Oslo University
Hospital, Oslo, Norway
4 Department of Pediatric Nephrology, 19 Mayis University Medical
School, Samsun, Turkey
5 Department of Pediatrics, Belarusian State Medical University,
Minsk, Belarus
6 Department of Internal Medicine and Nephrology “Dr Carol Davila”
Teaching Hospital of Nephrology, “Carol Davila” University of
Medicine and Pharmacy, Bucharest, Romania
7 Nephrology and Dialysis Unit, Pediatric Subspecialties Department,
Institute for Scientific Research, Bambino Gesù Children’s Hospital,
Rome, Italy
8 Department of Medicine, Zealand University Hospital,
Roskilde, Denmark
9 Department of Pediatric Nephrology and Transplantation, New
Children’s Hospital, University of Helsinki and Helsinki University
Hospital, Helsinki, Finland
10 Wilhelmina Children’s Hospital, University Medical Center,
Utrecht, The Netherlands
11 Department of Paediatric Nephrology, Royal Belfast Hospital for
Sick Children, Belfast, UK
12 Department of Paediatric Nephrology, Royal Bristol Hospital for
Children, Bristol, UK
13 Department of Nephrology and Internal Medicine, “Carol Davila”
University of Medicine and Pharmacy, Bucharest, Romania
14 Department of Nephrology, “Dr. Carol Davila” Teaching Hospital
of Nephrology, Bucharest, Romania
15 Department of Kidney Transplantation, Russian Children’s Federal
Clinical Hospital of Pirogov Russian National Research Medical
University, Moscow, Russia
16 Pediatric Nephrology, Department of Pediatrics, Faculty of
Medicine and University Hospital Cologne, University of Cologne,
Cologne, Germany
17 QiN-Group, Department of Medicine II, Faculty of Medicine and
University Hospital Cologne, University of Cologne,
Cologne, Germany
18 SBAL Pediatric Diseases, Nephrology and Hemodialysis Clinic,
Department of Pediatrics, Medical University of Sofia,
1606 Sofia, Bulgaria
19 Department of Pediatrics, Faculty of Medical Sciences in Zabrze,
Medical University of Silesia in Katowice, Katowice, Poland
20 Department of Multidisciplinary Pediatrics, Pediatric Nephrology
Unit, Assistance Publique des Hôpitaux de Marseille,
Marseille, France
21 Nephrology Unit, Kyriakou Children’s Hospital, Athens, Greece
22 Dialysis Unit, Department of Pediatrics, IRCCS Giannina Gaslini,
Genoa, Italy
23 Nephrology Department, University Children’s Hospital,
Belgrade, Serbia
24 Department of Pediatrics, Bordeaux University Hospital, Bordeaux
Population Health Research Center UMR 1219, University of
Bordeaux, Bordeaux, France
Pediatr Nephrol
